MYL6 Antibody

What is MYL6 and why is it important in scientific research?

MYL6 (Myosin Light Chain 6) is a 16.9 kDa protein encoded by the MYL6 gene in humans. It functions as an essential alkali light chain component of the myosin hexameric complex, which serves as a cellular motor protein with ATPase activity. MYL6 is expressed in smooth muscle and non-muscle tissues and plays crucial roles in cellular motility, cytoskeletal organization, and contractile functions. Research interest in MYL6 has grown due to its implication in various disease processes, including microscopic polyangiitis (MPA) and cancer cell migration, particularly in melanoma . The protein exists in multiple isoforms and is also known by several aliases including LC17, MLC3SM, ESMLC, LC17-GI, and LC17-NM .

What are the key differences between polyclonal and monoclonal MYL6 antibodies?

When selecting between polyclonal and monoclonal antibodies, researchers should consider their experimental needs. Polyclonal antibodies like those from Boster Bio (A09646) offer greater sensitivity through multiple epitope recognition, making them suitable for detection of native proteins . Conversely, monoclonal antibodies such as Proteintech's 68142-1-Ig provide higher specificity and consistency, especially important for quantitative experiments or when differentiating between closely related proteins .

How should MYL6 antibodies be stored to maintain optimal activity?

Most commercial MYL6 antibodies should be stored at -20°C for long-term preservation. For frequent use within one month, storage at 4°C is generally acceptable. The antibodies are typically supplied in buffer solutions containing stabilizers such as glycerol (often at 50%) and preservatives like sodium azide (0.02%) . It's crucial to avoid repeated freeze-thaw cycles as these can degrade antibody performance. For Boster Bio's A09646 antibody, the recommended storage is -20°C for one year, with short-term storage at 4°C for up to one month . Proteintech's preparation (68142-1-Ig) contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 and is stable for one year after shipment when stored at -20°C . Aliquoting is generally unnecessary for -20°C storage of glycerol-containing preparations.

What are the validated applications for MYL6 antibodies and their recommended dilutions?

The optimal dilution should be determined empirically for each experimental setup. For Proteintech's monoclonal antibody (68142-1-Ig), Western blot applications can use dilutions from 1:5,000 to 1:50,000, while IHC applications typically require 1:1,000 to 1:4,000 dilutions . Reactivity has been confirmed across multiple species including human, mouse, rat, pig, and rabbit samples .

How can I optimize MYL6 immunohistochemistry protocols for different tissue types?

For optimal MYL6 immunohistochemistry, tissue-specific antigen retrieval methods are crucial:

• Antigen Retrieval: For most tissues, heat-induced epitope retrieval (HIER) with TE buffer at pH 9.0 is recommended. Alternatively, citrate buffer at pH 6.0 may be used .

• Tissue-Specific Considerations:

  • Heart tissues: Longer antigen retrieval times (20-25 minutes) may be necessary due to dense muscle structure

  • Skeletal muscle: Similar to heart tissue protocols

  • Kidney tissue: Standard protocols are typically sufficient

  • Colon tissue: May require gentler antigen retrieval to preserve morphology

• Blocking and Antibody Incubation:

  • Use 3% BSA with 0.3% Triton X-100 for blocking

  • For primary antibody, incubate overnight at 4°C

  • For secondary antibody, incubate for 1 hour at room temperature

• Signal Enhancement:

  • For tissues with low MYL6 expression, consider using amplification systems (e.g., tyramide signal amplification)

  • Adjust counterstaining intensity based on tissue type

The Proteintech monoclonal antibody (68142-1-Ig) has been validated for IHC in human colon, human kidney, rat heart, mouse heart, and mouse/rat skeletal muscle tissues .

What controls should be included when using MYL6 antibodies in experimental procedures?

Robust experimental design with appropriate controls is essential for reliable results with MYL6 antibodies:

• Positive Controls:

  • Tissue samples: Heart tissue (particularly rich in MYL6)

  • Cell lines: A549, HeLa cells (known to express MYL6)

  • Recombinant protein: Purified MYL6 protein (e.g., from Novus Biologicals)

• Negative Controls:

  • Primary antibody omission: Replace primary antibody with host species IgG

  • Isotype control: Use matched isotype antibody (e.g., rabbit IgG for rabbit polyclonal antibodies)

  • Blocking peptide: Pre-incubate antibody with immunizing peptide to demonstrate specificity

• Validation Controls:

  • siRNA knockdown: Samples with MYL6 gene silencing (demonstrated reduction in signal)

  • Overexpression: Samples with MYL6 overexpression (demonstrated increase in signal)

  • Multiple antibodies: Use antibodies targeting different epitopes of MYL6

• Technical Controls:

  • Loading control: For Western blots (e.g., GAPDH, β-actin)

  • Molecular weight marker: To confirm correct band size (16.9 kDa, with variants up to 25 kDa)

  • Cross-reactivity assessment: Test antibody against closely related proteins (e.g., other myosin light chains)

For immunofluorescence studies, include DAPI nuclear counterstain and appropriate cytoskeletal markers (e.g., phalloidin for F-actin) to provide structural context .

How can I address non-specific binding issues with MYL6 antibodies?

Non-specific binding is a common challenge when working with MYL6 antibodies. To minimize this issue:

• Optimize Blocking Conditions:

  • Increase blocking agent concentration (try 5% BSA or 5% non-fat milk)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • Consider adding 5% normal serum from the secondary antibody host species

  • Extend blocking time to 2 hours at room temperature

• Antibody Dilution Optimization:

  • Perform titration experiments with serial dilutions (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Monoclonal antibodies may require higher dilutions (up to 1:50,000 for WB)

  • Consider longer incubation at lower antibody concentrations

• Washing Protocol Modification:

  • Add higher salt concentration to wash buffer (up to 500 mM NaCl)

  • Increase number of washes and washing time

  • Add 0.05% Tween-20 to wash buffers

• Sample Preparation Considerations:

  • For tissues with high endogenous biotin, use avidin/biotin blocking kit

  • Pre-absorb antibody with tissue powder from species of interest

  • For IHC, quench endogenous peroxidase with 3% H₂O₂ before antibody incubation

• Control Experiments:

  • Compare staining patterns between different MYL6 antibodies

  • Validate specificity through peptide competition

  • Use MYL6 knockdown samples as negative controls

Remember that MYL6 has reported isoforms and various species variants, which may contribute to differential recognition patterns across sample types .

Why might I observe multiple bands or unexpected molecular weights when detecting MYL6 via Western blot?

Multiple bands or unexpected molecular weights in MYL6 Western blots can be attributed to several biological and technical factors:

• Biological Explanations:

  • Isoforms: MYL6 has two reported isoforms (expected at 16.9 kDa)

  • Post-translational modifications: Phosphorylation or other modifications may shift apparent molecular weight

  • Splice variants: Alternative splicing can generate variants with different sizes

  • Species differences: MYL6 variants exist across species, including human, mouse, rat, canine, and porcine

• Technical Considerations:

  • Proteolytic degradation: Incomplete protease inhibition during sample preparation

  • Protein complexes: Incomplete denaturation may show higher molecular weight bands

  • Cross-reactivity: Antibody may recognize related myosin light chains

  • Non-specific binding: Particularly common with polyclonal antibodies

• Troubleshooting Approaches:

  • Sample preparation: Use fresh protease inhibitor cocktail

  • Denaturing conditions: Increase SDS concentration or heating time/temperature

  • Reducing agents: Ensure sufficient DTT or β-mercaptoethanol in sample buffer

  • Gel percentage: Use higher percentage gels (15-20%) for better resolution of low molecular weight proteins

  • Transfer conditions: Optimize for small proteins (higher methanol concentration, lower voltage)

  • Antibody validation: Compare results with different antibodies targeting distinct epitopes

The observed molecular weight range for MYL6 is typically 17-25 kDa according to Proteintech's validation data . If bands appear outside this range, further validation is recommended to confirm specificity.

How do I effectively troubleshoot weak or absent signals in MYL6 immunofluorescence staining?

Weak or absent signals in MYL6 immunofluorescence staining can be addressed through a systematic troubleshooting approach:

• Fixation and Permeabilization Optimization:

  • Fixation method: Compare paraformaldehyde (4%) with methanol fixation

  • Fixation time: Test different durations (10-20 minutes)

  • Permeabilization: Adjust Triton X-100 concentration (0.1-0.5%)

  • Epitope accessibility: Try different antigen retrieval methods (heat, enzymatic)

• Antibody Incubation Conditions:

  • Concentration: Decrease dilution factor (use more concentrated antibody)

  • Incubation time: Extend to overnight at 4°C

  • Temperature: Room temperature vs. 4°C incubation

  • Antibody selection: Try different clones or polyclonal vs. monoclonal

• Signal Enhancement Strategies:

  • Amplification systems: Tyramide signal amplification

  • Brighter fluorophores: Switch to higher quantum yield fluorophores

  • Mounting media: Use anti-fade mounting media with signal enhancers

  • Blocking optimization: Reduce background to improve signal-to-noise ratio

• Microscopy and Imaging Parameters:

  • Exposure settings: Increase exposure time

  • Gain settings: Increase detector gain

  • Objectives: Use higher NA objectives for better light collection

  • Image processing: Apply appropriate deconvolution algorithms

• Biological Considerations:

  • Expression levels: Confirm MYL6 expression in your cell type or tissue

  • Subcellular localization: MYL6 may have specific localization patterns

  • Cell treatment: Some stimuli may alter MYL6 expression or localization

For validated protocols, researchers have successfully used anti-MYL6 polyclonal antibody incubated overnight at 4°C, followed by secondary antibody coupled with Alexa Fluor 488, with simultaneous ActinRed 555 and DAPI counterstaining for 20 minutes at room temperature .

How can MYL6 antibodies be utilized to study neutrophil extracellular trap (NET) formation?

MYL6 antibodies have proven valuable in studying neutrophil extracellular trap (NET) formation, particularly regarding the role of actin rearrangement in this process:

• Experimental Design for NET Formation Studies:

  • Neutrophil isolation: Obtain peripheral blood neutrophils using density gradient separation

  • NET induction: Stimulate with phorbol 12-myristate 13-acetate (PMA, 20 nM)

  • Treatment groups: Include anti-MYL6 antibody (0.5 μg/mL) vs. control IgG

  • Time course analysis: Assess NET formation at multiple timepoints (30 min, 1h, 3h, 4h)

• Visualization and Quantification Methods:

  • DNA staining: DAPI to visualize extracellular DNA traps

  • NET markers: Co-stain for citrullinated histone H3 to confirm NET identity

  • Actin dynamics: Use phalloidin staining (e.g., Acti-stain 555) to visualize F-actin

  • G-actin visualization: Anti-β-actin antibody to track G-actin distribution

  • Quantification: Measure percentage of NET-forming cells and NET area

• Mechanistic Insights from Anti-MYL6 Intervention:

  • The presence of anti-MYL6 antibody disrupts G-actin polymerization into F-actin

  • This disruption suppresses PMA-induced NET formation

  • The effect suggests myosin-actin interaction is necessary for NET formation

  • The approach allows temporal analysis of cytoskeletal changes during NET formation

• Controls and Validation:

  • Isotype control: Use matched host species IgG (e.g., rabbit IgG)

  • Positive control: Confirm NET formation with PMA alone

  • Specificity validation: Confirm effects with multiple anti-MYL6 antibodies

These methodologies have revealed that anti-MYL6 antibody can suppress NET formation by disrupting actin rearrangement, specifically by interfering with G-actin polymerization into F-actin, which appears essential for NET formation .

What is the significance of anti-MYL6 antibodies in autoimmune disease research, particularly microscopic polyangiitis?

Anti-MYL6 antibodies have emerged as important biomarkers and potential pathogenic factors in autoimmune disease research, with particular significance in microscopic polyangiitis (MPA):

• Detection of Serum Anti-MYL6 Antibodies in Patients:

  • ELISA methodology: Recombinant human MYL6 immobilization on plates

  • Patient stratification: Identifying anti-MYL6 antibody-positive vs. negative MPA patients

  • Prevalence data: Found in approximately 7 of 59 patients with MPA (11.9%)

  • Cutoff determination: Using mean+1.5 standard deviation of healthy controls

• Clinical Correlations with Anti-MYL6 Antibody Status:

  • Disease activity: Lower Birmingham vasculitis activity score (BVAS) in antibody-positive patients

  • Organ involvement: Significantly lower cutaneous, cardiovascular, and nervous system involvement

  • Treatment response: Higher remission rates 6 months after initiation of therapy

  • Renal and pulmonary manifestations: No significant differences between antibody-positive and negative groups

• Mechanistic Implications in MPA Pathophysiology:

  • NET interference: Anti-MYL6 antibodies disrupt NET formation

  • Potential protective role: May limit tissue damage by reducing excessive NET formation

  • Prognostic marker: Potential utility in predicting disease course and treatment response

  • Diagnostic significance: May help identify a distinct subgroup of MPA patients

• Experimental Approaches for Studying Anti-MYL6 in MPA:

  • In vitro NET assays: Comparing NET formation between patient groups

  • Serum transfer experiments: Testing pathogenicity in animal models

  • Actin dynamics studies: Examining cytoskeletal effects in neutrophils

  • Therapeutic implications: Potential for targeted approaches based on MYL6 biology

This research has significant implications for understanding MPA heterogeneity, with anti-MYL6 antibody positivity potentially identifying a subgroup with distinct clinical manifestations and better prognosis .

How can MYL6 antibodies be employed to investigate cancer cell migration, particularly in melanoma?

MYL6 antibodies provide valuable tools for investigating cancer cell migration mechanisms, especially in melanoma where MYL6 plays a critical role:

• Experimental Models for Studying MYL6 in Melanoma Migration:

  • Cell lines: SkMel28, MeWo, A375, SkMel30 melanoma cells

  • Gene manipulation: ADCK2 knockdown affects MYL6 expression

  • Migration assays: Wound healing/scratch assays to quantify migration capacity

  • Molecular pathway analysis: Linking ADCK2-MYL6 axis to migration phenotypes

• Immunofluorescence Applications in Migration Studies:

  • MYL6 visualization: Anti-MYL6 antibody with Alexa Fluor 488 secondary antibody

  • Cytoskeletal co-labeling: ActinRed 555 for F-actin visualization

  • Nuclear counterstaining: DAPI for cell localization

  • Quantitative image analysis: Measuring MYL6 expression levels and subcellular distribution

• Mechanistic Studies Using MYL6 Antibodies:

  • Expression correlation: Visualizing reduced MYL6 after ADCK2 knockdown

  • Rescue experiments: MYL6 knockdown negates effects of ADCK2 overexpression

  • Functional connections: ADCK2 appears upstream of MYL6 in regulatory pathway

  • Migration phenotype: Increased migration after MYL6 knockdown in ADCK2 overexpressing cells

• Clinical Correlations from Database Analysis:

  • Expression data mining: Positive correlation between ADCK2 and MYL6 expression in melanoma

  • Survival analysis: Lower MYL6 expression correlates with poorer survival outcomes

  • Prognostic implications: Potential utility as biomarker for melanoma progression

These studies have revealed that MYL6 is functionally connected to ADCK2, with ADCK2 knockdown reducing MYL6 expression by 40-80% in melanoma cells. This reduction correlates with altered migration capacity, suggesting MYL6 as a critical mediator of migration control in melanoma .

How do commercially available MYL6 antibodies compare in terms of specificity and application range?

Selection criteria should be based on your specific experimental needs:

• For detection across multiple species, Proteintech's monoclonal antibody offers the broadest validated reactivity

• For highly sensitive Western blots, the high dilution range of Proteintech's antibody suggests superior sensitivity

• For immunohistochemistry applications, Sigma's HPA046859 offers validation through the Human Protein Atlas project

• For comprehensive epitope coverage, polyclonal options from Boster Bio or Biomatik may be preferable

The choice between monoclonal and polyclonal should consider the trade-off between specificity (favoring monoclonal) and sensitivity (often higher with polyclonal antibodies).

What methodological approaches are recommended for validating a new batch of MYL6 antibody?

Rigorous validation of new MYL6 antibody batches is essential for experimental reproducibility:

• Initial Characterization:

  • Concentration measurement: Absorbance at 280nm or BCA/Bradford assay

  • Purity assessment: SDS-PAGE with Coomassie staining

  • Immunoglobulin class verification: ELISA or immunodiffusion

  • Storage buffer composition check: pH and additive concentrations

• Functional Validation by Application:

  • Western blot:

    • Compare with previous batch using identical samples

    • Verify expected molecular weight (16.9-25 kDa)

    • Test across multiple sample types (cell lines, tissues)

    • Perform loading curve to determine sensitivity

  • Immunohistochemistry/Immunofluorescence:

    • Side-by-side staining with previous batch

    • Assess staining pattern and intensity

    • Test on known positive tissues (heart, muscle)

    • Include negative controls (primary antibody omission)

  • ELISA (if applicable):

    • Standard curve comparison with previous batch

    • Determine EC50 values

    • Assess background signal levels

    • Cross-reactivity testing

• Specificity Confirmation:

  • Peptide competition: Pre-incubation with immunizing peptide

  • Knockout/knockdown validation: Test on MYL6-depleted samples

  • Cross-reactivity assessment: Test on related proteins

  • Multiple antibody comparison: Compare with other MYL6 antibodies

• Documentation Requirements:

  • Validation image capture: Store raw and processed images

  • Detailed protocol recording: All conditions and reagents

  • Batch information documentation: Lot number, date, expiration

  • Performance metrics quantification: Signal-to-noise ratio, specificity scores

For example, when testing a new MYL6 antibody batch for Western blot, validation should include heart tissue samples from multiple species and cell lines such as A549 and HeLa, which serve as reliable positive controls .

How do I reconcile contradictory results between different MYL6 antibodies in my experiments?

Contradictory results between different MYL6 antibodies require systematic investigation to resolve discrepancies:

• Comprehensive Antibody Characterization:

  • Epitope mapping: Identify which region of MYL6 each antibody targets

  • Clone/lot information: Document all antibody details and sources

  • Application optimization: Each antibody may require different conditions

  • Format differences: Consider differences between conjugated vs. unconjugated forms

• Systematic Experimental Comparison:

  • Side-by-side testing: Use identical samples and protocols

  • Dilution series: Test each antibody across a range of concentrations

  • Protocol variations: Systematically modify fixation, blocking, incubation conditions

  • Positive controls: Include samples with confirmed high MYL6 expression

• Biological Explanations for Discrepancies:

  • Isoform specificity: Different antibodies may recognize different MYL6 isoforms

  • Post-translational modifications: Some epitopes may be masked by phosphorylation

  • Protein interactions: Complexed MYL6 may hide certain epitopes

  • Tissue/cell-specific expression patterns: Expression may vary between samples

• Validation Experiments to Resolve Contradictions:

  • Recombinant protein testing: Test against purified MYL6 protein

  • Knockdown/overexpression: Compare antibody signals in manipulation experiments

  • Mass spectrometry validation: Confirm protein identity in immunoprecipitated samples

  • Multi-omics correlation: Compare antibody results with RNA-seq or proteomics data

• Interpretation and Decision Framework:

  • Consensus approach: Focus on findings consistent across multiple antibodies

  • Literature cross-reference: Compare with published results using the same antibodies

  • Application-specific selection: Different antibodies may be optimal for different applications

  • Biological context consideration: Interpret results within your experimental system

For example, contradictory results in MYL6 expression patterns might be explained by the antibodies recognizing different forms of MYL6 (e.g., one recognizing total MYL6 while another detecting only non-phosphorylated forms). In such cases, using complementary techniques like RT-qPCR can help resolve protein-level discrepancies .

What is the current understanding of MYL6's role in actin dynamics and cellular motility?

The current understanding of MYL6's role in actin dynamics and cellular motility has evolved significantly through recent research:

• Molecular Interactions and Functions:

  • Myosin complex formation: MYL6 serves as an alkali light chain in the myosin hexameric complex

  • Actin binding regulation: Influences myosin-actin interactions during contractile processes

  • G-actin polymerization: Anti-MYL6 antibodies disrupt G-actin polymerization into F-actin

  • Cytoskeletal reorganization: Essential for cell shape changes during migration

• Cellular Processes Mediated by MYL6:

  • NET formation: Critical for neutrophil extracellular trap formation

  • Cancer cell migration: Controls melanoma cell motility

  • Contractile functions: Important in smooth muscle and non-muscle contractility

  • Cytoskeletal dynamics: Regulates dynamic actin rearrangements

• Regulatory Mechanisms:

  • ADCK2 connection: ADCK2 appears upstream of MYL6 in regulatory pathways

  • Expression control: ADCK2 knockdown reduces MYL6 expression by 40-80%

  • Functional relationship: MYL6 knockdown negates effects of ADCK2 overexpression

  • Pathway integration: Part of complex signaling networks controlling cell motility

• Experimental Evidence from Recent Studies:

  • Anti-MYL6 antibody effects: Disrupts actin reorganization and NET formation

  • Migration assays: Altered migration capacity correlates with MYL6 expression levels

  • Visualization studies: Immunofluorescence confirms subcellular distribution patterns

  • Gene expression correlations: ADCK2 and MYL6 expression show positive correlation

These findings collectively suggest that MYL6 functions as a critical regulator of actin dynamics, particularly in processes requiring cytoskeletal reorganization such as cell migration and specialized functions like NET formation .

How might MYL6 antibodies contribute to developing novel diagnostic or therapeutic approaches?

MYL6 antibodies show promising potential for novel diagnostic and therapeutic applications based on emerging research:

• Diagnostic Applications:

  • Autoimmune disease stratification: Identifying anti-MYL6 antibody-positive MPA patients (11.9% prevalence)

  • Prognostic biomarker: Anti-MYL6 antibody positivity correlates with lower disease activity and better treatment response

  • Cancer progression assessment: MYL6 expression levels as indicator of melanoma aggressiveness

  • Tissue-specific pathology: Evaluation of cytoskeletal abnormalities in muscle disorders

• Potential Therapeutic Approaches:

  • NET formation modulation: Targeting MYL6 to control excessive NET formation in inflammatory diseases

  • Migration inhibition: Disrupting MYL6 function to reduce cancer cell motility and metastasis

  • Autoantibody neutralization: Developing decoy targets for pathogenic anti-MYL6 antibodies

  • Cytoskeletal stabilization: MYL6-targeted approaches for disorders involving abnormal cellular contractility

• Drug Development Considerations:

  • Target validation: MYL6 antibodies as tools to validate the target in disease models

  • Mechanism studies: Elucidating pathways amenable to pharmacological intervention

  • Biomarker development: Companion diagnostics for treatment selection

  • Screening platforms: High-throughput systems using MYL6 antibodies for compound screening

• Challenges and Future Research Needs:

  • Specificity requirements: Ensuring targeted approaches don't disrupt essential functions

  • Delivery methods: Developing strategies to target intracellular MYL6

  • Combination approaches: Integrating MYL6-targeted therapies with existing treatments

  • Long-term effects: Understanding consequences of chronic MYL6 modulation

Current evidence suggests particularly promising applications in autoimmune vasculitis, where anti-MYL6 antibodies appear to define a distinct patient subgroup with lower disease activity and better treatment response . In cancer research, the connection between MYL6 and cell migration suggests potential for targeting metastatic processes .

What methodological innovations are emerging for studying MYL6's functions in different cellular contexts?

Methodological innovations for studying MYL6 functions across cellular contexts continue to evolve:

• Advanced Imaging Techniques:

  • Super-resolution microscopy: Visualizing MYL6 interactions at nanoscale resolution

  • Live-cell imaging: Tracking MYL6 dynamics during cellular processes in real-time

  • Correlative light-electron microscopy (CLEM): Combining functional and ultrastructural information

  • Expansion microscopy: Physical expansion of specimens for enhanced resolution

• Genetic Manipulation Approaches:

  • CRISPR/Cas9 genome editing: Generating precise MYL6 knockouts or mutations

  • Inducible expression systems: Temporal control of MYL6 expression

  • Domain-specific mutations: Structure-function analysis of MYL6 domains

  • Cell-specific conditional knockouts: Tissue-specific MYL6 deletion in animal models

• Protein Interaction and Functional Analysis:

  • Proximity labeling: BioID or APEX2 tagging to identify MYL6 interaction partners

  • Single-molecule pull-down: Analyzing individual MYL6 complexes

  • Advanced mass spectrometry: Identifying post-translational modifications and interaction networks

  • Optical tweezers/force spectroscopy: Measuring mechanical properties of MYL6-containing structures

• Translational Research Techniques:

  • Patient-derived organoids: Studying MYL6 in disease-relevant 3D models

  • Single-cell analysis: Examining MYL6 expression heterogeneity in tissues

  • Multi-omics integration: Correlating MYL6 protein data with transcriptomics and metabolomics

  • AI-assisted image analysis: Automated quantification of MYL6 localization patterns

• Emerging Application-Specific Methods:

  • Microfluidic migration assays: Precisely quantifying migration in response to MYL6 manipulation

  • NET formation quantification: Automated analysis of NET components and structures

  • Traction force microscopy: Measuring cell-generated forces dependent on MYL6 function

  • Intravital microscopy: Observing MYL6-dependent processes in living organisms